SB 204990
SB 204990 (CAS: 154566-12-8) is a selective inhibitor targeting ATP citrate lyase (ACLY), an enzyme critical for lipid biosynthesis. Through ACLY inhibition, SB 204990 suppresses fatty acid and cholesterol synthesis in HepG2 hepatocellular carcinoma cells, exhibiting concentration-dependent activity. In animal studies, oral administration at 25 mg/kg significantly lowers plasma lipoprotein concentrations, including VLDL, LDL, and HDL levels, in canine models, and reduces VLDL production alongside plasma cholesterol and triglycerides in rats. SB 204990 serves as a valuable tool for studying lipid metabolic pathways and developing lipid-lowering therapeutic strategies.
| Physical Appearance | White solid |
| Storage | Store at -20°C |
| M.Wt | 389.27 |
| Cas No. | 154566-12-8 |
| Formula | C18H22Cl2O5 |
| Solubility | insoluble in H2O; ≥51.2 mg/mL in DMSO; ≥59.4 mg/mL in EtOH |
| Chemical Name | 2-((3S,5R)-5-(6-(2,4-dichlorophenyl)hexyl)-3-hydroxy-2-oxotetrahydrofuran-3-yl)acetic acid |
| SDF | Download SDF |
| Canonical SMILES | ClC1=CC(Cl)=C(C=C1)CCCCCC[C@](O2)([H])C[C@](C2=O)(O)CC(O)=O |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment:[1] | |
|
Cell lines |
Hep G2 cells |
|
Reaction Conditions |
0 ~ 30 μM SB 204990 for 2.5 h incubation |
|
Applications |
SB 204990 caused a dose-dependent decrease in the rates of cholesterol and fatty acid synthesis in Hep G2 cells, measured by the incorporation of 3H into the sterol and fatty acid fractions of saponifiable cell lipids during a 2.5 h incubation. At 30 μM SB 204990, decreases in the rates of cholesterol and fatty acid synthesis were 91% and 82%, respectively. |
| Animal experiment:[1] | |
|
Animal models |
Male beagle dogs |
|
Dosage form |
10 mg/kg per day for 7 days, followed by 25 mg/kg per day for an additional 15 days Once daily by oral route |
|
Applications |
SB 204990, administered at 25 mg/kg for 15 days (after a 7-day starting period at a dose of 10 mg/kg), caused a significant and sustained decrease in fasting plasma cholesterol and triglyceride levels of up to 23%and 38%, respectively. SB 204990 significantly decreased cholesterol levels in the LDL and HDL fractions, with the effects on LDL being proportionately the greatest. |
|
Note |
The technical data provided above is for reference only. |
|
References: 1. Pearce NJ, Yates JW, Berkhout TA, et al. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochemical Journal, 1998, 334 (1):113-119. |
|
Quality Control & MSDS
- View current batch:
Chemical structure
